Skip to main content
Equibles
FLGT logo

FLGT · Fulgent Genetics, Inc.

Track FLGT — free

Use FLGT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$20.04 +0.45 (+2.30%) At close · Sep 2
Russell 2000 member Rebalance outlook locked
Market Cap
$540.13M
Shares
27.52M

FLGT metrics

68 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$19.59
Market cap
$540.13M

Price action

19 metrics
Price change (1W)
-1.8%
Price change (30D)
+11.2%
Price change (3M)
+4.8%
Price change (6M)
+42.1%
Price change (YTD)
-25.4%
Price change (1Y)
-11.6%
Trailing year
Price change (5Y)
-78.8%
52-week high
$30.85
52-week low
$13.79
Change from 52-week high
-36.5%
Change from 52-week low
+42.1%
Annualized volatility
59.4%
Beta
0.8
RSI (14D)
52.4
Price vs SMA 50
-0.2%
Price vs SMA 200
-6.0%
Avg volume (3M)
303,832
Relative volume
0.9
Average dollar volume
$5.80M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
27.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.7×
reciprocal yield 60.0%
P / book
0.5
reciprocal yield 185.4%
FCF yield
-19.2%
TTM · current market cap
Buyback yield
11.8%
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
11.8%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
35.6%
Operating margin
-37.7%
Trailing 12 months
Net margin
-25.9%
Gross profit (TTM)
$115.26M
Operating profit (TTM)
−$122.28M
Net income (TTM)
−$84.01M
Trailing 12 months
Diluted EPS (TTM)
$-0.31
FCF margin
-32.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+4.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$323.93M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-8.3%
Year over year · fewer shares
Revenue CAGR (3Y)
-19.5%
Revenue CAGR (5Y)
-5.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-8.4%
Return on assets
-7.7%
Debt / equity
—
Current ratio
6.3
EBITDA (TTM)
−$96.46M
Free cash flow (TTM)
−$103.79M
Quick ratio
6.3
Interest coverage
-1,019.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$26.30M
Latest balance sheet
Cash & equivalents
$26.30M
Total assets
$1.09B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$83.70M
Capital expenditures (TTM)
$20.09M
R&D (TTM)
$56.76M
SG&A (TTM)
—
Stock compensation (TTM)
$37.51M
R&D / revenue
17.5%
Stock compensation / revenue
11.6%

Ownership (13F)

3 metrics
13F filers
142
13F filer change QoQ
-17
Institutional ownership
57.5%

Short interest

3 metrics
Short interest
9.3%
Latest settlement · 9.3 days to cover
Days to cover
9.3d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$42,438
Insider-sentiment score
45 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1674930 CUSIP 359664109 13F (30d) 120 filings 111 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)